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Dedifferentiated thyroid cancer (DeTC) derived from follicular epithelium is often incurable because it does not respond to
radioiodine, radiotherapy, or chemotherapy. In cases, RET/PTC rearrangements are found in 30%–40%, RAS mutations in about
10%, and BRAF mutations in around 40%–50%, with no overlap between these mutations results in papillary thyroid cancer,
while a higher prevalence of BRAF mutations (up to 70%) has been observed in DeTC. The identification of these activating
mutations in DeTC makes this malignancy an excellent model to examine the effect of tyrosine kinase inhibitors (TKIs). Clinical
trials with several TKIs targeting RET, and to a lesser extent BRAF, and other TKRs have shown positive results, with about one-
third of DeTC showing a reduction in tumor size up to 50%, with the longest treatment duration of approximately three-four
years. Angiogenesis inhibitors have also shown promising activity in DeTC. Progress is being made toward effective targeted DeTC
therapy. The possibility of testing the sensitivity of primary DeTC cells from each subject to different TKIs could increase the
effectiveness of the treatment.
1. Introduction
Thyroid carcinoma is the most prevalent endocrine malig-
nancy and accounts for 1% of all human cancers. Approx-
imately 90% of thyroid malignancies are well-differentiated
thyroid carcinomas, which are classified as papillary or
follicular based on histopathological criteria. Even though
differentiated thyroid carcinomas are usually curable by the
combination of surgery, radioiodine ablation, and thyroid-
stimulating hormone suppressive therapy, recurrence occurs
in 20%–40% of patients [1, 2]. During tumor progression,
cellular dedifferentiation occurs in up to 5% of cases and is
usually accompanied by more aggressive growth, metastatic
spread, and loss of iodide uptake ability, making the
tumor resistant to the traditional therapeutic modalities and
radioiodine. Conventional chemotherapy and radiotherapy
have a modest, if any, effect on advanced dedifferentiated
thyroid cancer (DeTC) [3], which is responsible for a large
number of deaths attributed to thyroid cancer. Therefore,
advanced DeTC represents a therapeutic dilemma and is
considered a critical area of research.
2. Molecular Changes in DeTC
Iodide trapping is a thyrotropin- (TSH-) regulated mecha-
nism involving an energy-dependent transport mediated by
the Sodium/Iodine symporter (NIS) [3, 4] at the basolateral
surface of the thyrocyte and passive transport at the apical
surface, where a role has been suggested for the Pendred
syndrome (PDS) gene. At the apical surface the iodide is
organified by thyroperoxidase (TPO) and conjugated to
tyrosine residues on thyroglobulin (Tg). Amajor drop in NIS
transcripts has been demonstrated in primary andmetastatic
thyroid tumors by comparison with normal tissues, but
this is far less evident in metastases with no radioiodine
(131I) uptake than in primary cancers and metastases
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able to trap 131I, suggesting that mechanisms other than
a mere genetic control over NIS transcription might be
involved in this failure to trap 131I [5]. Tg, TPO, and
PDS gene expressions are lower in thyroid cancers than
in normal tissues. A significant gene expression decrease
of such molecules was also found in metastases with no
131I uptake by comparison with either primary cancers or
metastases with a positive 131I whole-body scan (WBS).
These differences could mean that a demonstrable 131I
uptake by thyroid cancers requires not only a functional and
correctly located NIS but also the full machinery responsible
for iodide retention in the cell. Indirect confirmation of
this hypothesis seems to come from gene therapy studies,
where the NIS gene was introduced in nonthyroid cancer
cells to promote 131I uptake and induce cytotoxicity. Such
reports demonstrated that althoughNIS delivery in the target
cells was followed by an efficient iodine uptake, therapeutic
effects were only observed when high doses of radioiodine
(beyond the ranges used in humans) were administered [5].
For cancers failing to trap 131I, the availability of imaging
procedures to detect metastatic disease is crucial to the use
of surgery with a curative intent [1]. Several reports have
demonstrated the effectiveness of fludeoxyglucose-positron
emission tomography (FDG-PET) in the postoperative man-
agement of thyroid cancers, particularly in patients with high
serum Tg levels and negative 131I WBS. Such effectiveness
is consistent with different molecular studies showing that
the higher glucose consumption in primary cancers is
accompanied by an increase in its transmembrane transport
due to GLUT-1 overexpression; this increase correlates with
more aggressive histotypes and the presence of local and
distant metastases. The FDG-PET scan’s sensitivity might
be improved by TSH stimulation. Preliminary in vitro
studies have demonstrated that TSH stimulation in FRTL-
5 cells is followed by an increased glucose uptake, and
subsequent in vivo studies have demonstrated that the FDG-
PET scan became more accurate after administering recom-
binant human TSH, revealing lesions not seen in conditions
of TSH suppression and inducing changes in the extent
of surgery and ameliorating management and outcome
[1].
Moreover, recently it has been shown that BRAF muta-
tion in papillary thyroid cancer is associated with a more
aggressive phenotype and less differentiated state due to
decreased expression of iodide-metabolizing [6] and sodium
iodide symporter genes [7].
Furthermore, the BRAF V600E oncogene induces trans-
forming growth factor-beta secretion leading to sodium
iodide symporter repression and increased malignancy in
thyroid cancer [8], and targeted expression of BRAF V600E
in thyroid cells of transgenic mice results in papillary thyroid
cancers that undergo dedifferentiation [9].
3. Oncogenes
Molecular abnormalities, believed to cause thyroid cancer,
have been recorded in papillary and follicular thyroid
carcinomas. In 80% of papillary thyroid carcinomas (PTCs),
mutations have been noted in genes that encode signaling
molecules of the mitogen-activated protein kinase (MAPK)
pathway [10]. In adult sporadic papillary carcinomas, RET/
PTC rearrangements are found in 30%–40% of cases, RAS
mutations in about 10% of cases, and BRAF mutations
in around 40% of cases, with no overlap between these
mutations [5, 11]. In radiation-induced papillary carcinomas
and those in childhood, RET/PTC rearrangements have been
seen in 50%–80% of cases and BRAF mutations in 10% of
cases [5, 11]. Inhibitors of BRAF kinase block the growth of
thyroid cancer cells that have RET/PTC or BRAF mutations
[12].
In a recent study, MEK inhibitor CI-1040 has been
found to abrogate tumor growth in BRAF mutant xenografts
derived from various tumor types [13].
Furthermore, a recent study demonstrated that treatment
of cells with MEK inhibitors could restore the expression of
Tg and NIS [14].
In addition to the activation of the MAPK pathway,
these mutations and most tyrosine kinase receptors can also
result in the activation of the phosphatidylinositol 3-kinase
[15, 16].
Of the several forms of RET/PTC, RET/PTC1 and RET/
PTC3 are the most frequently found in PTC [17]. RET/PTC
tyrosine kinases are constitutively active and trigger the
activation of signaling pathways by interacting with and
phosphorylating several signaling molecules.
Activation of RET/PTC in cultured thyroid cells results
in downregulation of expression of Tg and NIS and cell
dedifferentiation [18, 19]. These effects of RET/PTC acti-
vation require signaling along the MAPK pathway [20]
and, more specifically, the presence of the functional BRAF
kinase [21]. Indeed, BRAF silencing in cultured thyroid
cells reverses the RET/PTC-induced effects such as ERK
phosphorylation [18]. However, signaling from the wild-
type RET receptor and its truncated RET/PTC forms is also
known to activate a number of other pathways, particularly
the phosphatidylinositol-3 kinase/AKT pathway, which may
also contribute to its biological effects [22, 23].
BRAF mutations have been associated with more aggres-
sive and less differentiated papillary tumors, and this is
consistent with the inhibition of thyroid-tumor cell growth
induced by the blockade of BRAF kinase.
Recently, the effect of a BRAF small inhibitory RNA
construct and the BRAF kinase inhibitor AAL881 on both
BRAF wild-type and mutant thyroid carcinoma cell lines
was evaluated. A small inhibitory RNA construct targeting
the expression of both wild-type BRAF and BRAF V600E
induced a comparable reduction of viability in both wild-
type and BRAF V600E mutant cancer cells. Interestingly,
AAL881 inhibited MEK and ERK phosphorylation and
induced apoptosis preferentially in BRAF V600E-harboring
cells than wild-type ones, possibly because of better
inhibitory activity against BRAF V600E [24].
Recently, it was investigated whether sensitivity to MEK
inhibition was determined by oncogene status in 13 human
thyroid cancer cell lines: four with BRAF mutations, four
RAS, one RET/PTC1, and four wild type. Thyroid cancers
with BRAF mutation were preferentially sensitive to MEK
inhibitors (PD0325901, AZD6244) whereas tumors with
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other MEK-ERK effector pathway gene mutations have
variable responses [25].
Overexpression of tyrosine kinase receptors has been
noted in thyroid cancer cells, including those for fibroblast
growth factor, epidermal growth factor (EGF), hepatocyte
growth factor (c-Met), vascular endothelial growth factor
(VEGF), insulin, and insulin growth factor 1. The ligands
for these receptors are also often overexpressed. Angiogenesis
might also have a crucial role in the development of these
hypervascularised tumors, and the expression of angiogenic
markers can have prognostic significance [26–28]. In exper-
imental models, antivascular treatment blocks the growth of
DeTC [29, 30].
4. New Molecular Targeted Therapies in
Advanced Thyroid Cancer
Activated oncogenes are highly attractive targets for the
development of new specific anticancer agents. A growing
number of drugs that target an activated oncogene are
already showing benefits to patients in clinical applications,
thereby demonstrating the potential of oncogene inhibition
in human cancer. In addition, other drugs that target acti-
vated or overexpressed oncogenes at different mechanistic
levels have recently been approved, such as the EGF receptor
(EGFR) inhibitors and VEGF andVEGF receptor-2 (VEGFR-
2) inhibitors, which can prevent tumor angiogenesis [31, 32].
All of these examples illustrate that patients with cancer
can significantly profit from the development of targeted
therapies, especially when an activated oncogene is proven
to be the underlying cause for a given malignancy. However,
all these new small molecules demonstrated a higher activity
when administered in combination with chemotherapeutic
drugs [32].
One highly promising target for the development of a
selective therapy for the treatment of patients with PTC
is the activated RET oncogene [33]. The RET/PTC family
of chimeric oncogenes result from several rearrangements
involving the RET gene of chromosome 10q; they are specific
to papillary carcinomas and are present in up to 77% of these
tumors. The proteins product of the RET/PTC oncogenes
all contain the intracellular tyrosine kinase domain of the
normal RET proto-oncogene product and can therefore be
immunohistochemically detected with an antibody to the
carboxy terminus of RET [34], even if this technique may
be problematic. The search for new therapeutic options,
therefore, becomes increasingly important, especially for
patients with metastatic disease. Since somatic mutations in
RET are known to be causative for the development of PTC,
activated RET is the most obvious target for a new strategy
to treat this disease.
Moreover, there are recent experimental evidences of
autocrine activation of EGFRs and VEGFRs in PTC cell lines
(e.g., TPC1 cells) [35] that suggest a particular rationale for
the use of tyrosine kinase inhibitors with dual modes of
action such as ZD6474 [36] and SU11248 [33]. Furthermore,
these compounds can also effectively act through the inhibi-
tion of tumor angiogenesis, a key process of the neoplastic
growth in thyroid cancers [37].
To date a number of structurally different compounds
have been reported as ATP-competitive inhibitors of the
tyrosine kinase activity of RET. They include quinazolines,
such as ZD6474 [36], indolin-2-ones, that are RPI-1 [38]
and SU5416 [39], and pyrazolo[3,4-d]pyrimidines, like PP1
[40] and PP2 [41], all showing various degrees of efficacy
and specificity with respect to other tyrosine kinases. The
pyrazolopyrimidine derivatives PP1 and PP2, in particular,
proved to be the most potent compounds, showing IC50
values of 80 and 100 nM, respectively. Moreover, they are
also good inhibitors of protooncogene Src, a key downstream
RET effector. Therefore, these compounds are proposed
for a multiple-signal transduction strategy, which may
have therapeutic potential for the management of thyroid
carcinomas. The anilinoquinazoline ZD6474 is an oral small-
molecule inhibitor of VEGFR and EGFR tyrosine kinases and
is currently implicated in several phase I and phase II trials
[42]. ZD6474 was also found to target the RET kinase in
mammalian cell cultures and to efficiently block the invasive
growth of cancer cells [36]. However, these new small
molecules are highly effective in combination with standard
chemotherapy. Among chemotherapeutic drugs, preclinical
studies using irinotecan seem to be very promising in
different types of thyroid carcinomas such as anaplastic and
medullary ones, especially in combination with treatments
with anti EGFR antibodies (cetuximab) and small molecules
inhibiting tyrosine kinases (PTK787) [43–45].
5. Clinical Activity of New Molecular Targeted
Therapies in Advanced Thyroid Cancer
The clinical activity of several compounds, including mote-
sanib diphosphate (AMG 706), BAY 43-9006, ZD 64-74,
and AG-013736, in DeTC is being studied in phase II
trials [33, 46–49], with preliminary studies recording partial
response and stabilization [50–52]. These molecules inhibit
several targets, including RET tyrosine kinase, VEGFR1,
VEGFR2, and VEGFR3, and have an antiangiogenic effect.
BAY 43-9006 also inhibits BRAF kinase. Other targets include
membrane receptor kinases, such as those for EGF, platelet-
derived growth factor, and c-Met. Any clinical effect of each
of these drugs could be related to the inhibition of theMAPK
pathway and of angiogenesis and possibly to the inhibition of
other targets.
The results obtained with some of these agents are
interesting. Axitinib, a selective inhibitor of VEGFR 1, 2,
and 3, was investigated in the therapy of sixty patients with
advanced thyroid cancer. Partial responses were observed
in 18 patients. Stable disease lasting > or = 16 weeks was
reported in another 23 patients. The authors conclude that
Axitinib has antitumor activity in all histologic subtypes of
advanced thyroid cancer [53].
AMG 706 (a novel oral inhibitor of VEGFR, platelet-
derived growth-factor receptor, and KIT) was used in the
treatment (125mg administered orally once daily) of 93
patients with progressive, locally advanced or metastatic,
radioiodine-resistant differentiated thyroid cancer. The
objective response rate was 14%; stable disease was achieved
in 67% of the patients, and stable disease was maintained for
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24 weeks or longer in 35%. The authors concluded that AMG
706 can induce partial responses in patients with advanced or
metastatic differentiated thyroid cancer [54].
An open-label phase II trial with sorafenib (that inhibits
a spectrum of kinases including Raf kinase, VEGFR, platelet-
derived growth factor receptor, and RET tyrosine kinases)
was conducted in patients with advanced, metastatic, iodine-
refractory thyroid carcinoma. Thirty patients were treated
for a minimum of 16 weeks. Seven patients (23%) had a
partial response lasting 18 to 84 weeks. Sixteen patients
(53%) had stable disease lasting 14 to 89 weeks. The authors
concluded that Sorafenib has clinically relevant antitumor
activity in patients with metastatic, iodine-refractory thyroid
carcinoma, with an overall clinical benefit rate (partial
response + stable disease) of 77% [55].
In another study of 41 PTC patients treated with
Sorafenib, six patients had a partial response (PR 15%;
95% CI, 6 to 29) and 23 patients (56%; 95% CI, 40 to
72) had stable disease longer than 6 months. The authors
concluded that Sorafenib is reasonably well-tolerated therapy
with clinical and biologic antitumor activity in metastatic
PTC [56].
6. Choice of the Optimal Treatment
New therapeutic approaches against DeTC are under devel-
opment. However, more research is needed to finally identify
therapies able to control and to cure this disease.
There are still some limitations in the selective use of
novel compounds. There might be several potential targets
in a given tumor, and most compounds can hit multiple
targets, so the most important target for a given tumor
might remain uncertain. Even when potential targets (such
as RET) are present in the tumor tissue, tumor response
might be observed in only a fraction of patients. A lack
of response can occur, for instance, because target inhibi-
tion raises the activity of compensatory signal pathways,
which, in turn, rescues tumor cell growth. Moreover, the
possibility of testing the sensitivity of primary DeTC cells
from each subject to different tyrosine kinase inhibitors
could increase the effectiveness of the treatment; in fact,
in vitro chemosensitivity tests are able to predict in vivo
effectiveness in 60% of cases [57]. While, it is well known
that a negative chemosensitivity test in vitro is associated
with a 90% of ineffectiveness of the treatment in vivo [57],
allowing the administration of inactive chemotherapeutics to
these patients to be avoided [58–60].
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